Vertex Pharmaceuticals executive Joy Liu reported an open-market sale of company stock. On July 1, 2026, she sold 828 shares of Vertex common stock at an average price of $502.71 per share.
After this transaction, Liu directly holds 19,131 Vertex shares. The sale was executed under a pre-arranged Rule 10b5-1 trading plan that she entered into on November 25, 2025, indicating the trades were scheduled in advance rather than timed at her discretion.
Vertex Pharmaceuticals reported a proposed sale notice on Form 144 listing 1,541 shares of Common Stock associated with Fidelity Brokerage Services LLC. The filing also lists restricted stock vesting events of 612 shares on 02/17/2026 and 929 shares on 02/24/2026.
VRTX filed a Form 144 reporting proposed sales of Common Stock by Joy Liu and an entry showing Fidelity Brokerage Services LLC. The filing lists multiple proposed dispositions with specific trade dates, share counts and gross proceeds: examples include 04/01/2026 — 978 shares for $439,288.26, 05/01/2026 — 1,104 shares for $469,222.08, and 06/01/2026 — 828 shares for $364,245.48.
The filing also shows a broker/recipient line for Fidelity Brokerage Services LLC with a listed figure 416,243.88 and another numeric entry 253805417 with an associated date 07/01/2026. The form records the method as Restricted Stock Vesting and classifies the transactions as Compensation.
Vertex Pharmaceuticals executive Dr. Carmen Bozic, EVP and CMO, sold 596 shares of Common Stock in an open-market transaction. The sale took place on June 26, 2026 at a price of $482.50 per share, for total proceeds of about $287,570.
The transaction was made under a company-approved Rule 10b5-1 trading plan that Dr. Bozic entered into on November 20, 2025, indicating it was pre‑scheduled rather than opportunistic. Following the sale, she directly owns 15,337 shares of Vertex common stock.
VRTX affiliate filed a Form 144 reporting proposed and recent sales of Common Stock. The filing lists a proposed sale tied to restricted stock vesting on 02/24/2026 for 596 shares and multiple actual sale transactions by Carmen R. Bozic between 03/27/2026 and 06/18/2026, with per‑trade share counts and gross proceeds shown.
The filings identify Fidelity Brokerage Services LLC as the broker and show the securities are listed on NASDAQ. The notice is a routine affiliate resale disclosure under Form 144.
Vertex Pharmaceuticals executive Carmen Bozic reported an open-market sale of company stock. As EVP and Chief Medical Officer, Bozic sold 1,020 shares of Vertex Pharmaceuticals common stock at a price of $462.17 per share on June 18, 2026.
After this transaction, Bozic directly holds 15,933 shares of Vertex common stock. The filing notes that the sale was made under a company-approved Rule 10b5-1 trading plan, which was entered into on November 20, 2025, indicating the trade was pre-scheduled rather than timed discretionarily.
Vertex Pharmaceuticals notice of proposed sale relates to Common stock tied to a restricted stock vesting event of 1,020 shares dated 02/17/2026. The filing also lists recent open-market dispositions by Carmen R. Bozic totaling multiple transactions between 03/27/2026 and 06/15/2026 with individual share counts and proceeds disclosed.
Vertex Pharmaceuticals EVP and CMO Carmen Bozic reported an open-market sale of common stock. On June 15, 2026, she sold 4,062 shares of Vertex common stock at $450.00 per share. After this transaction, she directly holds 16,953 shares.
The sale was executed under a pre-arranged Rule 10b5-1 trading plan approved by the company and entered into on November 20, 2025. This indicates the timing of the sale was set in advance as part of a structured trading program.
Filer submitted a Form 144 notice reporting a proposed sale of 4,062 shares of Common Stock on 06/15/2026. The filing lists $1,827,900.00 alongside 253,805,417 (appearing on the same cover line). The filing also records recent sales by Carmen Bozic, including 2,329 shares on 03/27/2026 and 6,988 shares on 05/12/2026.